<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38947026</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2693-5015</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Research square</Title><ISOAbbreviation>Res Sq</ISOAbbreviation></Journal><ArticleTitle>Real-World Effectiveness of Nirmatrelvir in Protecting Long COVID for Outpatient Adult Patients - A Large-Scale Observational Cohort Study from the RECOVER Initiative.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">rs.3.rs-4536807</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.21203/rs.3.rs-4536807/v1</ELocationID><Abstract><AbstractText>Paxlovid has been approved for use in patients who are at high risk for severe acute COVID-19 illness. Evidence regarding whether Paxlovid protects against Post-Acute Sequelae of SARS-CoV-2 infection (PASC), or Long COVID, is mixed in high-risk patients and lacking in low-risk patients. With a target trial emulation framework, we evaluated the association of Paxlovid treatment within 5 days of SARS-CoV-2 infection with incident Long COVID and hospitalization or death from any cause in the post-acute period (30-180 days after infection) using electronic health records from the Patient-Centered Clinical Research Networks (PCORnet) RECOVER repository. The study population included 497,499 SARS-CoV-2 positive patients between March 1, 2022, to February 1, 2023, and among which 165,256 were treated with Paxlovid within 5 days since infection and 307,922 were not treated with Paxlovid or other COVID-19 treatments. Compared with the non-treated group, Paxlovid treatment was associated with reduced risk of Long COVID with a Hazard Ratio (HR) of 0.88 (95% CI, 0.87 to 0.89) and absolute risk reduction of 2.99 events per 100 persons (95% CI, 2.65 to 3.32). Paxlovid treatment was associated with reduced risk of all-cause death (HR, 0.53, 95% CI 0.46 to 0.60; risk reduction 0.23 events per 100 persons, 95% CI 0.19 to 0.28) and hospitalization (HR, 0.70, 95% CI 0.68 to 0.73; risk reduction 2.37 events per 100 persons, 95% CI 2.19 to 2.56) in the post-acute phase. For those without documented risk factors, the associations (HR, 1.03, 95% CI 0.95 to 1.11; risk increase 0.80 events per 100 persons, 95% CI -0.84 to 2.45) were inconclusive. Overall, high-risk, nonhospitalized adult patients with COVID-19 who were treated with Paxlovid within 5 days of SARS-CoV-2 infection had a lower risk of Long COVID and all-cause hospitalization or death in the post-acute period. However, Long COVID risk reduction with Paxlovid was not observed in low-risk patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9459-9461</Identifier><AffiliationInfo><Affiliation>Weill Cornell Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zang</LastName><ForeName>Chengxi</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8244-9551</Identifier><AffiliationInfo><Affiliation>Weill Cornell Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Haoyang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Weill Cornell Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khullar</LastName><ForeName>Dhru</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Weill Cornell Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yongkang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Weill Cornell Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strobel</LastName><ForeName>Stephenson</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Weill Cornell Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sala</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Northwestern University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Payal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Washington School of Medicin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comellas</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wylam</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>6Patient representative for Long COVID patients with the National Institutes of Health's RECOVER Initiative.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5586-9940</Identifier><AffiliationInfo><Affiliation>Weill Cornell Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Children's Hospital of Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carton</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Louisiana Public Health Institute.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaushal</LastName><ForeName>Rainu</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4694-2517</Identifier><AffiliationInfo><Affiliation>Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OT2 HL161847</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Res Sq</MedlineTA><NlmUniqueID>101768035</NlmUniqueID><ISSNLinking>2693-5015</ISSNLinking></MedlineJournalInfo><CoiStatement>Additional Declarations: There is NO Competing Interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>1</Day><Hour>5</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38947026</ArticleId><ArticleId IdType="pmc">PMC11213188</ArticleId><ArticleId IdType="doi">10.21203/rs.3.rs-4536807/v1</ArticleId><ArticleId IdType="pii">rs.3.rs-4536807</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solving the puzzle of Long Covid | Science.   https://www.science.org/doi/10.1126/science.adl0867?s=09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adl0867?s=09</ArticleId><ArticleId IdType="pubmed">38386747</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P (2021) Long covid&#x2014;mechanisms, risk factors, and management. BMJ n1648 10.1136/bmj.n1648</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ (2023) Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21:133&#x2013;146</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris EFDA (2023) Grants Full Approval to Paxlovid, COVID-19 Antiviral Treatment. JAMA. 10.1001/jama.2023.9925</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.9925</ArticleId><ArticleId IdType="pubmed">37285173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J et al. (2022) Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med 386:1397&#x2013;1408</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS et al. (2024) Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study. J Med Virol 96:e29333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10786003</ArticleId><ArticleId IdType="pubmed">38175151</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung KW, Baye F, Baik SH, McDonald CJ (2023) Nirmatrelvir and Molnupiravir and Post&#x2013;COVID-19 Condition in Older Patients. JAMA Intern Med 183:1404&#x2013;1406</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10594174</ArticleId><ArticleId IdType="pubmed">37870856</ArticleId></ArticleIdList></Reference><Reference><Citation>Suran M (2024) Studies Investigate Whether Antivirals Like Paxlovid May Prevent Long COVID. JAMA 331:98&#x2013;100</Citation><ArticleIdList><ArticleId IdType="pubmed">38090997</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z (2023) Association of Treatment With Nirmatrelvir and the Risk of Post&#x2013;COVID-19 Condition. JAMA Intern Med. 10.1001/jamainternmed.2023.0743</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond Jennifer et al. (2024) Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19. N Engl J Med 390:1186&#x2013;1195</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11156287</ArticleId><ArticleId IdType="pubmed">38598573</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H et al. (2022) Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med 1&#x2013;10. 10.1038/s41591-022-02116-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02116-3</ArticleId><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Wang W, Leaf DE (2022) Target Trial Emulation: A Framework for Causal Inference From Observational Data. JAMA 328:2446&#x2013;2447</Citation><ArticleIdList><ArticleId IdType="pubmed">36508210</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang C et al. (2023) Data-driven analysis to understand long COVID using electronic health records from the RECOVER initiative. Nat Commun 14:1948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10080528</ArticleId><ArticleId IdType="pubmed">37029117</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. People with Certain Medical Conditions (2023) Centers for Disease Control and Prevention; 
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html</Citation></Reference><Reference><Citation>Xu S et al. (2010) Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence Intervals. Value Health 13:273&#x2013;277</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351790</ArticleId><ArticleId IdType="pubmed">19912596</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34:3661&#x2013;3679</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626409</ArticleId><ArticleId IdType="pubmed">26238958</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang C et al. (2023) High-throughput target trial emulation for Alzheimer&#x2019;s disease drug repurposing with real-world data. Nat Commun 14:1&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10713627</ArticleId><ArticleId IdType="pubmed">38081829</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA (2022) 10.1001/jama.2022.18931</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold BF, Ercumen A (2016) Negat Control Outcomes JAMA 316:2597&#x2013;2598</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5428075</ArticleId><ArticleId IdType="pubmed">28027378</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>